

#50742

Date: July 18, 2022

Subject: GSK plc - Distribution/Share Consolidation Option Symbol: GSK New Symbol: GSK1 Date: 07/19/2022

GSK plc (GSK) has announced a distribution of (New) Haleon plc (HLN) American Depositary Shares. The distribution ratio is 1.0 of an HLN share for each existing GSK share held. The record date is July 15, 2022; the payable date is July 21, 2022. **GSK ADSs will be without the value of HLN, effective July 19, 2022.**

Immediately following the distribution, also on July 19, 2022, GSK ADSs will undergo a share consolidation at a ratio of 4 for 5. As a result, each existing GSK ADS will be converted into the right to receive 0.80 of a (New) GSK ADS.

Haleon plc American Depositary Shares began trading on a when issued basis on July 18, 2022 on the NYSE under the trading symbol "HLN WI". (New) Post-Split GSK American Depositary Shares will begin trading on a when issued basis on July 19, 2022 on the NYSE under the trading symbol "GSK WI". HLN and GSK both are expected to begin regular way trading on July 22, 2022.

Contract Adjustment

Effective Date:	July 19, 2022
Option Symbol:	GSK changes to GSK1
Strike Prices:	No Change
Number of Contracts:	No Change
Multiplier:	100 (e.g., a premium of 1.50 yields \$150; a strike of 45 yields \$4,500.00)
New Deliverable Per Contract:	 80 (New) GSK plc (GSK) American Depositary Shares (subject to delayed settlement until regular way trading commences) 100 (New) Haleon plc (HLN) American Depositary Shares (subject to delayed settlement until regular way trading commences)
Settlement Allocation:	GSK: 80% HLN: 20%

CUSIPs:

THE SETTLEMENT ALLOCATION OF THE TOTAL STRIKE PRICE AMOUNT IS BEING PROVIDED SOLELY FOR THE PURPOSE OF THE INTERFACE BETWEEN OCC AND THE NATIONAL SECURITY CLEARING CORPORATION (NSCC), AND IS NOT INTENDED TO BE USED FOR ANY OTHER PURPOSE, TRANSACTION OR CUSTOMER ACCOUNT STATEMENTS.

Delayed Settlement

OCC will delay settlement of the GSK and HLN components of the GSK1 deliverable until regular way trading of GSK and HLN shares commences. Upon commencement of regular way trading, OCC will require Put exercisers and Call assignees to deliver the appropriate number of GSK and HLN shares.

Pricing

The underlying price for GSK1 will be determined as follows:

GSK1 = .80 (GSK) + HLN

Disclaimer

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, please email the Investor Education team at options@theocc.com. Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email memberservices@theocc.com.